Human papilloma virus 56 type L1 protein mutant, method for reducing degradation of recombinant protein and application of human papilloma virus 56 type L1 protein mutant

• Main Authors: ZHANG HAIJIANG, YIN FEI, ZHANG RUIXIA, SHEN ERCUI, JIANG XULIN, CHEN XIAO, LIU YONGJIANG, WU SHUMING, WANG XUEHONG, XUE JUNLIAN
• Format: Patent
• Language: Chinese; English
• Published: 04.07.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention relates to the field of medical biology, and discloses a human papilloma virus 56 type L1 protein mutant, a method for reducing degradation of recombinant human papilloma virus 56 type L1 protein and application of the human papilloma virus 56 type L1 protein mutant. According to the invention, the 420th site R of the HPV56L1 amino acid sequence is mutated into T or Q by adopting a gene engineering technology, so that the degradation problem of the HPV56L1 amino acid sequence is successfully solved. Experiments show that the mutation does not influence the expression of the corresponding mutated L1 protein, the degradation proportion of the modified VLP protein is obviously reduced, and the immunogenicity of the corresponding VLP is not influenced. Therefore, after mutation modification is carried out on the human papilloma virus 56 type L1 protein, the degradation problem of the human papilloma virus 56 type L1 protein is avoided, the manufacturing difficulty is reduced, and the quality charact